Celularity (CELU) AI Stock Analysis

• Market Cap: $62.19M
• Dividend Yield: N/A
• Average Volume (3M): 108.27K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.51
• Revenue Growth: 4.45%
• EPS Growth: 45.19%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -1.02
• Shares Outstanding: 26,691,477
• 10 Day Avg. Volume: 192,291
• 30 Day Avg. Volume: 108,269
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.87
• Enterprise Value/Revenue: 2.15
• Enterprise Value/Gross Profit: 2.57
• Enterprise Value/Ebitda: -2.66
• 1Y Price Target: $6.00
• Price Target Upside: 157.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: $2.50 ▲(7.30% Upside)

Celularity's overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges and high leverage. Technical analysis indicates potential for a reversal, but current trends are bearish. Valuation is weak due to negative earnings. Positive corporate events have improved financial flexibility, providing some support to the score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, enhancing long-term business prospects.

Debt Reduction

Reducing debt improves financial flexibility and reduces interest expenses, strengthening the company's balance sheet over time.

Operational Efficiency

Improved gross margins reflect better cost management and operational efficiency, supporting long-term profitability potential.

Negative Factors

High Leverage

High leverage poses financial risks, limiting flexibility and increasing vulnerability to economic downturns, impacting long-term stability.

Profitability Challenges

Ongoing profitability issues highlight challenges in covering operational costs, potentially hindering sustainable growth and investor confidence.

Negative Cash Flow

Negative cash flow indicates cash drain, necessitating external funding, which could dilute equity and impact long-term financial health.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Celularity generates revenue primarily through the development and commercialization of its cell-based therapies. Key revenue streams include upfront payments, milestone payments, and royalties from partnerships with pharmaceutical companies and research institutions. The company may also earn revenue through licensing agreements for its proprietary technologies and products. Significant partnerships with larger biotech and pharmaceutical companies enhance its capabilities and market reach, contributing to its earnings through collaborative research and development agreements.

Celularity Financial Statement Overview

Summary

Celularity is experiencing robust revenue growth, yet profitability remains a challenge with substantial losses. The balance sheet indicates high leverage and declining equity, raising concerns about financial stability. Cash flows are negative but improving slightly, supported by financing activities. The company needs to focus on improving profitability and managing debt to enhance its financial health.

Income Statement

Celularity has shown a significant increase in revenue, growing from $22.8 million in 2023 to $54.2 million in 2024. However, the company remains unprofitable with a negative net profit margin due to high operational expenses, as indicated by negative EBIT and EBITDA margins. The gross profit margin improved to 83.6% in 2024 from 29.7% in 2023, which is a positive sign of operational efficiency.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.29 in 2024, indicating financial risk. The equity ratio is low at 6.7%, showing limited equity buffer. The stockholders' equity has decreased significantly, reflecting potential financial instability and risk.

Cash Flow

Celularity's free cash flow remains negative, but has improved from -$42.7 million in 2023 to -$6.56 million in 2024. The operating cash flow to net income ratio is negative, highlighting ongoing cash drain. However, the company successfully raised funds through financing activities, providing some liquidity cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.22M	22.77M	17.98M	21.34M	14.28M
Gross Profit	39.23M	6.75M	-1.69M	11.68M	9.35M
EBITDA	-43.71M	-183.95M	23.58M	-88.11M	-202.41M
Net Income	-57.89M	-196.29M	14.19M	-100.12M	-208.23M
Balance Sheet
Total Assets	132.68M	143.89M	401.07M	414.13M	431.01M
Cash, Cash Equivalents and Short-Term Investments	738.00K	227.00K	13.97M	37.24M	54.31M
Total Debt	68.84M	65.42M	65.59M	31.14M	30.64M
Total Liabilities	123.84M	102.93M	202.16M	314.71M	962.41M
Stockholders Equity	8.84M	40.96M	198.90M	99.42M	-531.40M
Cash Flow
Free Cash Flow	-6.56M	-42.73M	-143.11M	-116.30M	-91.03M
Operating Cash Flow	-6.40M	-38.69M	-137.88M	-110.10M	-63.19M
Investing Cash Flow	514.00K	-4.05M	-5.24M	-5.90M	-12.81M
Financing Cash Flow	6.70M	24.09M	119.84M	98.56M	102.01M

Celularity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 2.33 is below the 20-day moving average (MA) of 3.20, below the 50-day MA of 2.98, and above the 200-day MA of 2.20, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 37.36 is Neutral, neither overbought nor oversold. The STOCH value of 14.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$77.76M	―	-69.96%	―	-99.64%	-59.17%
STTK	55 Neutral	$94.85M	―	-73.39%	―	-27.33%	34.66%
Sector *	51 Neutral	$8.02B	-0.31	-43.38%	2.24%	22.31%	-2.14%
GBIO	50 Neutral	$40.48M	―	-85.45%	―	61.15%	54.71%
CELU	46 Neutral	$62.19M	―	-6367.24%	―	4.45%	45.19%
LTRN	45 Neutral	$42.44M	―	-88.59%	―	―	-8.47%
FBLG	38 Underperform	$23.66M	―	-559.73%	―	―	43.68%

Celularity Corporate Events

Celularity Achieves Nasdaq Compliance with Recent Filing

On September 2, 2025, Nasdaq informed Celularity Inc. that the company is in compliance with Listing Rule 5250(c)(1), following the filing of its Form 10-Q for the periods ending March 31, 2025, and June 30, 2025. This resolution closes the matter, indicating that Celularity has met the necessary regulatory requirements, which may positively impact its market standing and reassure stakeholders.

Celularity Sells IP to Celeniv, Reduces Debt

On August 13, 2025, Celularity Inc. entered into an asset purchase agreement with Celeniv Pte. Ltd., selling certain intellectual property for $33,812,230, which was used to retire all senior secured debt. The agreement included a license back of the IP to Celularity with a five-year repurchase option. This restructuring eliminated $41.6 million in debt, improved financial flexibility, and led to the creation of four wholly-owned subsidiaries to enhance operational efficiency across its commercial units.

Celularity Enters Series Seed Stock Agreement with Defeye

Celularity Inc. entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. on August 5, 2025, involving the issuance of 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits. Additionally, Celularity faced compliance issues with Nasdaq due to a delay in filing its quarterly report for the quarter ended March 31, 2025. The company submitted a compliance plan on August 1, 2025, and was given until August 31, 2025, to file the necessary reports to avoid delisting.

Celularity Issues Promissory Note and Warrant

On July 21, 2025, Celularity Inc. issued a promissory note worth $6,812,230 to an investor, along with a warrant to purchase 3,700,000 shares of Class A common stock at $2.528 per share, exercisable for five years. The note, bearing a 2% annual interest rate and maturing on March 21, 2026, is secured by the company’s assets and will be partially used to settle a loan from C.V. Starr & Co. This financial maneuver is expected to impact Celularity’s operations by addressing existing debt obligations and potentially influencing its market positioning.

Celularity Secures $2M Through Private Placement Deal

On July 14, 2025, Celularity Inc. entered into a securities purchase agreement with an institutional investor for a private placement of 1,230,769 shares of Class A common stock and warrants, expecting gross proceeds of $2,000,000. The company plans to use the net proceeds for working capital and general corporate purposes, potentially impacting its operational capacity and market positioning.

Celularity Finalizes Private Placement Agreement

On June 23, 2025, Celularity Inc. entered into a securities purchase agreement with certain investors for a private placement of 739,286 shares of Class A common stock at $1.40 per share. The agreement also included a warrant adjustment for 1,311,093 warrants, revising the exercise price to $2.50 per share and extending the expiration date to June 30, 2030. The closing is expected during the week of July 21, 2025, with gross proceeds anticipated at $1,035,000, intended for working capital and general corporate purposes.